-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Biogen, Raises Price Target to $215

Benzinga·08/03/2026 18:37:53
Listen to the news
Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $200 to $215.